PhD Scientific Days 2025

Pathological and Oncological Sciences I.

Blood-based prognostic biomarkers in small cell lung cancer

Előadó neve

Dr. Pozonec Veronika

Neptun code

IB0XR7

Előadó munkahelye

National Institute of Oncology, Budapest

Előadó telefonszáma

0038631747397

Előadó e-mail címe

pozonec.veronika@oncol.hu

Az előadás címe

Blood-based prognostic biomarkers in small cell lung cancer

Szerző(k) neve és munkahelye

Dr. Veronika Pozonec¹, Lilla Horvath², Kristiina Boettiger³, Beáta Szeitz², Christian Lang⁴, Anna Szantho⁵, Ildiko Kovacs², Vivien Teglas⁵, Maria Dorothea Pozonec⁵, Büsra Ernhofer³, Robert Szegedi⁶, Karin Schelch³, Clemens Aigner³, Krisztina Bogos⁶, Ferenc Renyi-Vamos⁵, Reka Hecz⁷, Gabriella Galffy⁷, Jeovanis Gil Valdes⁸, Gyorgy Marko-Varga⁹, Zsolt Megyesfalvi¹⁰, Balazs Döme¹¹

1: National Koranyi Institute of Pulmonology, Budapest, Hungary; Multidisciplinary Department of Head and Neck Cancer, National Institute of Oncology, Budapest
2: National Koranyi Institute of Pulmonology, Budapest, Hungary
3: Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
4: Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Pulmology, Department of Medicine II, Medical University of Vienna, Vienna, Austria
5: National Koranyi Institute of Pulmonology, Budapest, Hungary; Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary
6: National Koranyi Institute of Pulmonology, Budapest, Hungary;
7: Pulmonology Hospital Törökbálint, Törökbálint, Hungary
8: Department of Biomedical Engineering, Lund, Sweden
9: Department of Translational Medicine, Lund University, Lund, Sweden
10: National Koranyi Institute of Pulmonology, Budapest, Hungary; Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary
11: National Koranyi Institute of Pulmonology, Budapest, Hungary; Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary; Department of Translational Medicine, Lund University, Lund, Sweden

Bemutatás módja

Szóbeli

Szekció

Pathological and Oncological Sciences I.

Language of the presentation

English

Preferred session

Pathological and Oncological Sciences

Összefoglaló szövege

INTRODUCTION: Small cell lung cancer (SCLC) is known for its high proliferation rate,
aggressive nature and high metastatic potential. There hasn’t been any major breakthroughs in its clinical approach for decades. Recently, SCLC studies started focusing on biomarker research.
AIMS: We aimed to identify the prognostic value of circulating proteins in SCLC patients through proteomic profiling.
METHODS: We collected and analyzed blood samples and clinical data of 144 SCLC patients from the National Korányi Institute of Pulmonology, Budapest and the Medical University of Vienna. Mass spectrometry-based proteomics was performed at Lund University and quantified 1,338±209.23 protein samples. For the identification of prognostic biomarkers we used Multivariate Cox regression model, a custom-built machine-learning program and a weighted gene co-expression network analysis (WGCNA). Progression-free survival and potential predictive proteins related to SCLC were also examined. We also explored the therapy induced adverse reactions.
RESULTS: The majority of SCLC patients in our cohort presented with metastatic disease (69.44%), the median age was 68.73 years and 63.08% of patients were male. 60 proteins prognostic for OS (adj. p<0.05) were discovered through multivariate Cox regression analysis (with clinical data known at time of sample collection). CHGA expression significantly denoted poorer OS (multivariate hazard ratio, HR=1.44, adj. p<0.001). WGCNA results showed six distinct modules, or groups of co-expressed proteins. Interestingly, the modules MEpink and MEdarkred were associated with worse (HR=2.41, p=0.034) and better prognosis (HR=0.05, p=0.030), respectively. Select modules also yielded significant clinical variables (e.g. existence of liver metastasis for MEpink or female gender for MEdarkred). Pathway enrichment revealed relevant pathways such as ‘coagulation’ or ‘complement cascade’.
CONCLUSIONS: Our study identified prognostic proteins for OS through proteomic profiling and bioinformatical analysis. Additional studies for biomarker discovery are essential for the long awaited innovations in the clinical approach of SCLC.
FUNDING: VP was supported by the EKÖP-2024-156 New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Developement and Innovation Fund.

University

Semmelweis University

Supervisor

Dr. Megyesfalvi Zsolt

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem hagyta jóvá

Előadó

8065

Start

16:00

End

16:15